These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30474216)

  • 1. Multilevel model with random effects for clustered survival data with multiple failure outcomes.
    Tawiah R; Yau KKW; McLachlan GJ; Chambers SK; Ng SK
    Stat Med; 2019 Mar; 38(6):1036-1055. PubMed ID: 30474216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multilevel models for survival analysis with random effects.
    Yau KK
    Biometrics; 2001 Mar; 57(1):96-102. PubMed ID: 11252624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multilevel mixture cure models with random effects.
    Lai X; Yau KK
    Biom J; 2009 Jun; 51(3):456-66. PubMed ID: 19588451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixture cure models with time-varying and multilevel frailties for recurrent event data.
    Tawiah R; McLachlan GJ; Ng SK
    Stat Methods Med Res; 2020 May; 29(5):1368-1385. PubMed ID: 31293217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rhDNase as an example of recurrent event analysis.
    Therneau TM; Hamilton SA
    Stat Med; 1997 Sep; 16(18):2029-47. PubMed ID: 9308130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multilevel survival modelling of recurrent urinary tract infections.
    Wang K; Yau KK; Lee AH; McLachlan GJ
    Comput Methods Programs Biomed; 2007 Sep; 87(3):225-9. PubMed ID: 17619063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonproportional hazards and unobserved heterogeneity in clustered survival data: When can we tell the difference?
    Balan TA; Putter H
    Stat Med; 2019 Aug; 38(18):3405-3420. PubMed ID: 31050028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multilevel modelling of clustered grouped survival data using Cox regression model: an application to ART dental restorations.
    Wong MC; Lam KF; Lo EC
    Stat Med; 2006 Feb; 25(3):447-57. PubMed ID: 16143989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease.
    Christopher F; Chase D; Stein K; Milne R
    J Clin Pharm Ther; 1999 Dec; 24(6):415-26. PubMed ID: 10651974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
    Shak S
    Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human deoxyribonuclease for cystic fibrosis.
    Jones AP; Wallis CE
    Cochrane Database Syst Rev; 2003; (3):CD001127. PubMed ID: 12917899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical analysis of the long-term effects of recombinant human deoxyribonuclease on pulmonary function in cystic fibrosis patients.
    Chen JJ; Hamilton SA
    J Biopharm Stat; 2000 Aug; 10(3):287-97. PubMed ID: 10959912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marginal analysis for clustered failure time data.
    Lu SE; Wang MC
    Lifetime Data Anal; 2005 Mar; 11(1):61-79. PubMed ID: 15747590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
    Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
    N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis--an overview.
    Hodson ME
    Respiration; 1995; 62 Suppl 1():29-32. PubMed ID: 7792438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A readily available improvement over method of moments for intra-cluster correlation estimation in the context of cluster randomized trials and fitting a GEE-type marginal model for binary outcomes.
    Westgate PM
    Clin Trials; 2019 Feb; 16(1):41-51. PubMed ID: 30295512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A positive stable frailty model for clustered failure time data with covariate-dependent frailty.
    Liu D; Kalbfleisch JD; Schaubel DE
    Biometrics; 2011 Mar; 67(1):8-17. PubMed ID: 20528861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of model misspecification in shared frailty survival models.
    Gasparini A; Clements MS; Abrams KR; Crowther MJ
    Stat Med; 2019 Oct; 38(23):4477-4502. PubMed ID: 31328285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling multivariate survival data by a semiparametric random effects proportional odds model.
    Lam KF; Lee YW; Leung TL
    Biometrics; 2002 Jun; 58(2):316-23. PubMed ID: 12071404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the mean hazard ratio parameters for clustered survival data with random clusters.
    Cai J; Zhou H; Davis CE
    Stat Med; 1997 Sep; 16(17):2009-20. PubMed ID: 9304770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.